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the tokoloshe (which is also now allegedly responsible for 
spreading HIV infection).3
It has often been argued that the search for answers to age-
old conundrums cannot always be found in scientific study. 
Beliefs are just what they are and should be left alone. But 
this instance does beg the question: Could the tokoloshe be 
the experience of a stimulated indusium griseum? And do we 
here in Africa have a pre-programmed tokoloshe homunculus 
waiting to be activated in times of distress, dreamlike states 
or during a seizure? And lastly, but most challengingly, can a 
tokoloshe homunculus be imaged by fMRI during an episode?
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HRT prescriptions linked to 25% of 
breast cancers in California
To the Editor: I am a breast radiologist, running a 
multidisciplinary breast care centre together with two surgeons 
and a practitioner in oncology. We add about 90 - 100 new 
cancer cases to our files annually.
I am amazed to see how we doctors persist in our old ways 
of prescribing medicine and how reluctant we are to change, 
despite recent data. Our medical history is flawed with 
mistakes that sometimes took hundreds of years to correct 
(400 years to admit that vitamin C prevents scurvy, decades to 
admit that Semmelweis was right in washing hands and that 
bloodletting had no benefit). It took the USA’s Food and Drug 
Administration (FDA) 37 years to ban diethylstilbestrol, after 
the first synthetic oestrogen caused vaginal cancer in female 
babies.
Despite many colleagues criticising the composition of 
the Women’s Health Initiative (WHI) study1 on hormones, 
it nevertheless had a major impact on breast cancer figures. 
Women became scared, stopped their prescriptions, and then 
… breast cancer figures tumbled – for the first time in 30 years2 
– and in the 1970s also dropped after the scare of oestrogen 
causing endometrial cancer.3
The Stanford University Group could find no other cause of 
the unprecedented drop – other than women stopping their 
HRT prescriptions.4,5 A calculation by Donald A Berry, Cancer 
Research Professor of Biostatistics, Anderson Cancer Center, 
shocked us: that 25% of breast cancers in California before 2002 
could have been caused by HRT prescriptions.6 Which means 
that we, well-meaning doctors, caused cancer in our patients. 
This was 67 years after Dr Charles Dodds (inventor of the first 
synthetic oestrogen, diethylstilbestrol) and Dr Boris Shimkin 
warned that it caused cancer in their laboratory rats and that 
we did not know what the long-term effect might be on the 
human female!7
It is high time that our patients be informed about the side-
effects of prescription drugs and encouraged to make their 
own decisions, irrespective of whether the drug is thalidomide, 
Vioxx or HRT. After all, hormones are misused in a non-disease 
state like the menopause. How long will it take us to discard 
the financial gains, to admit that we are harming many of our 
patients, and to start changing our prescription habits?
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Medical aid double standards
To the Editor: I am distressed by obvious discrepancies in 
clinical standards applied by medical aids.
A friend, due for delivery of her first baby, was under the 
care of a midwife. When she went into labour, the midwife 
was unable to find her a bed at the birthing unit because all the 
beds were occupied by women who had had elective caesarean 
sections (CS). Eventually she laboured and delivered in a 
suboptimal side-room, with poor facilities for monitoring and 
delivery. She was then moved into a regular room, but she was 
told that she could only use it until the morning of the next 
day because it had been booked for another woman having an 
elective CS.
There are only a few institutions to which a midwife can 
directly admit women, and seemingly these few places are 
oversubscribed by largely unnecessary cases.
Elective CSs at maternal request are more costly, with longer 
recovery periods than elective vaginal delivery, with no clear 
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benefit to either mother or infant. I cannot understand how 
medical aids support this practice by agreeing to fund them. 
Many private obstetric practices have CS rates of well over 70% 
– three times the World Health Organization recommended 
rate. Surely some form of justification is required for 
procedures that are of no medical or obstetric benefit to a 
patient?
Our medical aid publishes a detailed schedule of benefits 
every year. It interests me that the fund chooses to limit certain 
benefits for recognised and manageable conditions, which must 
place a significant number of people in financial problems. 
Psychiatric benefits (for our scheme) are capped at R20 000 
per year per family; this includes all outpatient consultations 
and therapy sessions, as well as any cost of any admission 
required. If a member has a major depressive episode requiring 
admission (which is usually an extended admission, requiring 
at least a week), and then needs ongoing weekly therapy 
sessions (a vital part of mental health management), this 
capped amount would very soon be used up.
However, the fund is happy to pay for known ‘lifestyle’ 
diseases, with no cap on available funds at all. Conditions 
secondary to chronic smoking and alcohol consumption are not 
excluded, and the many and varied complications of obesity 
are happily paid for. Any attempt at improvement of health 
is excluded, or only minimally funded (e.g. dietician visits, 
therapy sessions), but the consequences of unhealthy living are 
supported.
There must be a way for medical aids to restructure the 
benefits they offer to promote healthy living and wise choices. 
At the moment, we can eat, drink and be merry because we’ll 
all be bailed out when problems arise; but if we don’t, and 
our mood slips, we’ll be queuing up at the poorly staffed 
government mental health services because our funds will only 
last a week or so.
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